Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN10597
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN10597 is an experimental recombinant fusion protein developed by Regeneron Pharmaceuticals. It is designed as a multi-functional immunotherapy that combines inhibition of the interleukin-2 receptor alpha chain (IL2RA) and programmed cell death protein 1 (PD-1). The molecule acts as both an IL2RA inhibitor and a PD-1 inhibitor, aiming to enhance anti-tumor immune responses by blocking two key immunosuppressive pathways in the tumor microenvironment. It is being investigated for use in advanced malignant solid neoplasms, including melanoma and renal cell carcinoma. As of June 2025, it is undergoing Phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[1][2][3][4][5].
- Other names
- REGN10597REGN-10597REGN 10597
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on REGN10597.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN10597.